Boston Scientific, Ajax Health and KKR have collaborated to create FlowMod, a new organisation intended to accelerate the creation, clinical validation, and regulatory approval for a system treating heart failure. The collaboration uses intellectual property developed by Boston Scientific.
“On the heels of the Cortex transaction with Boston Scientific, we are thrilled to pursue this new path in interventional heart failure and the benefits it may bring to the millions of patients affected by this disease each year,” said Duke Rohlen, chief executive officer, Ajax Health. “Through this collaboration, we intend to bring a differentiated solution to physicians and their patients that we believe will make a positive impact on how heart failure is treated.”
“We are pleased to collaborate with both Ajax Health and Boston Scientific, innovate productively alongside leading strategic partners, and help advance promising medical technology for the benefit of cardiovascular disease patients worldwide,” said Ali Satvat, partner and global head of health care strategic growth at KKR.
FlowMod will be led by chief executive officer Philippe Marco, former president and chief operations officer of Epix Therapeutics and CV Ingenuity, both of which were Ajax-led companies that obtained pre-market approval for groundbreaking cardiovascular devices.
“I am excited to work with the Ajax Health and KKR leadership teams again,” said Marco. “We look forward to developing a meaningful advancement in the treatment of patients with heart failure, building upon the foundation established by Boston Scientific.”
KKR is investing in FlowMod through its KKR Health Care Strategic Growth Fund II, a US$4 billion fund focused on investing in high-growth healthcare companies.
